Figure 3. Efficacy of the antibodies in humanized DKO mice.

% tumor growth of IMR-32 neuroblastoma was shown. Treatment schedules, doses of antibodies were detailed in the Methods and Results. Data shown as mean + SEM (n = 5); * P < 0.05 determined by Student t test when IgG1n group was compared with other three treatment groups, respectively. Two independent experiments were performed, with one representative set of data was presented.